The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis

Huddam B., Basaran M., Kocak G., Azak A., Yalcin F., Reyhan N. H. , ...Daha Fazla

INTERNATIONAL UROLOGY AND NEPHROLOGY, cilt.47, sa.8, ss.1423-1428, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47 Konu: 8
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s11255-015-1015-z
  • Sayfa Sayıları: ss.1423-1428


Encapsulated peritoneal sclerosis (EPS) is a rare complication of long-term peritoneal dialysis usually associated with the inadequacy and early termination of dialysis modality. Adequate treatment of peritoneal fibrosis has not been achieved by medical intervention so far. Mycophenolate mofetil (MMF), which inhibits inosine monophosphate dehydrogenase reversibly and highly selectively, is the most widely used drug for maintenance immunosupression in renal transplantation. Recent studies have shown that MMF has also antifibrotic effects. In this study, we evaluated the effects of MMF on EPS model in rats based on antifibrotic effects.